GenCanna Acquires London-Based CBD Provider, CBD Capital
WINCHESTER, Ky. — GenCanna, announced that it has acquired CBD Capital Ltd, provider of CBD distillate, isolate, and water-soluble bulk ingredients as well as white and private label services to the United Kingdom, the European Union and markets worldwide. CBD Capital CEO, Hassan Akhtar, will continue to serve in his current role.
The acquisition of CBD Capital enables GenCanna to broaden its bulk CBD product offering and distribution capabilities to its overseas customers, as well as expand its formulation capabilities and business-to-business operations through CBD Capital’s network of valued partners. CBD Capital also brings with it several sub-brands that will now enjoy accelerated product development and market expansion as more resources are devoted to them. The addition of CBD Capital follows GenCanna’s acquisition of London-based CBD finished goods formulator and brand accelerator, Taylor Mammon, further anchoring GenCanna’s footprint across the global CBD market.
“The highly strategic acquisition of CBD Capital widens and solidifies GenCanna’s leadership position across high-growth CBD markets in the United Kingdom, the European Union, and the rest of the world,” said Andrew Barnett, CEO of GenCanna. “As a long-term partner of CBD Capital, we are deeply familiar with its impressive business, which will significantly boost GenCanna’s ability to provide our growing global customer base with deepened and broadened services — such as greater formulation capability and expanded finished goods versatility, increased supply chain flexibility, and quick-to-market turnaround. We look forward to leveraging CBD Capital’s strong industry experience and passion as we develop end-to-end, turnkey solutions that speed sales and maximize gross margin dollars for our customers. This is the GenCanna way.”
With CBD Capital’s recent opening of a new base in Rotterdam, Netherlands, which facilitates next-day distribution capabilities to markets throughout the European Union, the company is strategically and logistically positioned to further growth and market penetration. “We are thrilled to join the growing family of GenCanna CBD companies,” said CBD Capital CEO Hassan Akhtar. “The injection of both financial and human capital, combined with GenCanna’s formidable CBD ingredient extraction and refinement sciences, and its sterling compliance track record, will now greatly facilitate the expansion and completion of several key channel strategies and market growth initiatives currently within the CBD Capital pipeline.”
(This information is primarily sourced from CBD Capital. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Latest News
Innocan Pharma Reports Significant Revenue Growth and Impressive Gross Profit in Q1 2023
LOS ANGELES-- Innocan Pharma Corporation, a pharmaceutical technology company specializing in innovative drug delivery platform technologies, has announced its financial results for the first quarter ended March 31, 2023. The company reported significant growth in ...
Minnesota Legalizes Adult-Use or Recreational Cannabis
ST PAUL, MN–Minnesota Governor Tim Walz, a Democrat, made a significant move on Tuesday by signing a bill that legalizes the recreational use of cannabis in the state. With this signature, Minnesota becomes the 23rd ...
Canopy Growth Acquires 19.99% Stake in Indiva, Secures Distribution Rights for Wana Edibles in Canada
LOS ANGELES-- In a strategic move to expand its presence in the cannabis edibles market, Canadian cannabis producer Canopy Growth has announced the acquisition of a 19.99% stake in edibles manufacturer Indiva. The deal also ...